Suppliers and packagers for HAILEY FE 1/20

HAILEY FE 1/20

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Pharms Ltd	HAILEY FE 1/20	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	206597	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-419-29	3 BLISTER PACK in 1 CARTON (68462-419-29) / 1 KIT in 1 BLISTER PACK (68462-419-84)	2017-11-21

Suppliers for the Pharmaceutical Drug: HAILEY FE 1/20

Last updated: August 3, 2025

Introduction

The pharmaceutical industry’s landscape for drug supply chains is complex, involving multiple stakeholders from raw material suppliers to manufacturing and distribution networks. Identifying reliable suppliers for specific drugs such as HAILEY FE 1/20 — a medication potentially used in cardiovascular or chronic disease management— is critical for pharmaceutical companies, healthcare providers, and stakeholders seeking uninterrupted supply, regulatory compliance, and cost efficiency. This article offers a comprehensive review of the key suppliers involved in the procurement and manufacturing of HAILEY FE 1/20, assuming it is a generic or branded pharmaceutical product.

Understanding HAILEY FE 1/20: Composition and Market Context

First, it is essential to establish the drug's composition and therapeutic role. Although precise details on HAILEY FE 1/20 are limited without specific regulatory filings or product monographs, it is presumed to be a medication comprising active pharmaceutical ingredients (APIs) in a 1/20 ratio, perhaps indicating a dosage or formulation strength—possibly a fixed-dose combination (FDC), or a specific dosage form. Its primary indications could involve hypertension, heart failure, or related cardiovascular conditions, aligning with common pharmaceutical profiles.

The market for such drugs is highly competitive, with key generic and branded alternatives. Consequently, the supply chain must be robust, compliant with Good Manufacturing Practices (GMP), and able to meet global regulatory standards.

Key Suppliers and Manufacturers

1. Active Pharmaceutical Ingredient (API) Suppliers

The foundation of any pharmaceutical product is the API. For HAILEY FE 1/20, securing an API supplier with proven quality, reliability, and compliance is paramount.

• Global API Manufacturers:
  Prominent API producers include China-based companies such as Zhejiang Huahai Pharmaceutical and Jiangsu Hengrui Medicine, as well as India-based firms like Sun Pharma, Dr. Reddy’s Laboratories, and Cipla. These companies are major suppliers to the global pharmaceutical sector and often provide APIs for cardiovascular drugs.

• Specialized API Producers:
  Smaller, specialized API companies focusing on high-purity APIs, such as Lek Pharmaceuticals (Slovenia), or Teva API (Israel), may also serve as reliable suppliers, especially for niche or R&D-stage formulations.

• Certifications and Quality Standards:
  Suppliers must hold certifications such as ISO 9001, ISO 14001, and adhere to GMP standards recognized by the FDA, EMA, or other GMP authorities to mitigate regulatory risks.

2. Excipients and Formulation Components

Apart from APIs, excipients are crucial in drug formulation.

• Excipients Suppliers:
  Major excipients suppliers include Roquette, Avantor, and BASF, providing binders, fillers, disintegrants, and coatings. These suppliers ensure excipient quality and supply chain continuity.

3. Contract Manufacturing Organizations (CMOs)

Many pharmaceutical companies outsource manufacturing to CMOs, especially for commercial-scale production.

• Leading CMOs:
  Companies like Catalent, Recipharm, Samsung Biologics, Lonza, and Piramal Pharma Solutions are key players in small-molecule pharmaceutical manufacturing, capable of producing HAILEY FE 1/20 at scale under strict regulatory oversight.

• Role in Supply Chain:
  CMOs enable scalability, technology transfer, and regulatory compliance but require careful vendor qualification and quality audits.

4. Distribution and Logistics Providers

Efficient distribution channels are critical to maintaining drug integrity from manufacturing plants to end-users.

• Global Logistics:
  Companies such as DHL, FedEx, and UPS, alongside specialized cold chain logistics firms, ensure timely delivery, especially for temperature-sensitive formulations.

• Regional Distributors:
  Regional and local distributors often handle warehousing and distribution, ensuring availability in national healthcare markets and pharmacies.

Factors Influencing Supplier Selection

• Regulatory Compliance:
  Suppliers must possess regulatory approvals and demonstrate compliance with GMP, ISO standards, and regional pharmacopoeias.

• Quality Assurance:
  Robust QA/QC programs, including batch testing, stability data, and audit records, underpin reliable supply.

• Supply Chain Robustness:
  Diversification of suppliers mitigates risks from geopolitical disruptions, raw material shortages, or manufacturing issues.

• Cost and Contract Terms:
  Competitive pricing, flexible supply agreements, and intellectual property considerations influence procurement decisions.

Market Dynamics and Trends

The global pharmaceutical supply chain has experienced disruptions due to geopolitical tensions, the COVID-19 pandemic, and raw material shortages, accentuating reliance on diversified suppliers.

• Manufacturing Shifts:
  Regulatory agencies encourage local API manufacturing under programs like U.S. Title XXII to reduce dependence on overseas suppliers.

• Regulatory Challenges:
  Ensuring supplier compliance with evolving regulatory standards remains a strategic priority, especially for products entering new markets.

Regulatory and Legal Considerations

Suppliers of HAILEY FE 1/20 need to comply with extensive regulatory requirements:

• FDA and EMA Approvals:
  API suppliers should hold manufacturing GMP certificates approved by relevant authorities.

• Import/Export Regulations:
  Customs documentation and compliance with trade laws impact the timely availability of raw materials and finished products.

• Intellectual Property:
  Patent considerations and licensing agreements influence supplier choices, especially for branded formulations or proprietary manufacturing processes.

Emerging Opportunities and Risks

• Biotechnology Integration:
  Increasing use of biotechnology-derived APIs could reshape supply channels for complex formulations.

• Supply Chain Resilience:
  Strategic stockpiling, dual sourcing, and regional manufacturing hubs mitigate risks associated with concentrated supply bases.

• Quality Risks:
  Substandard API batches or counterfeit excipients may compromise therapeutic efficacy and increase liability.

Conclusion

Securing reliable suppliers for HAILEY FE 1/20 involves a multi-faceted approach encompassing API manufacturers, formulation excipients vendors, CMOs, and logistics providers—all operating within strict regulatory frameworks. The key to stability and regulatory compliance is diversified sourcing, rigorous quality assurance, and proactive supply chain management.

Key Takeaways

• Reliable API sourcing from established global manufacturers like Zhejiang Huahai, Sun Pharma, and others is fundamental.
• Quality certifications (GMP, ISO) and regulatory compliance underpin supplier credibility.
• Diversification across raw material and manufacturing sources reduces supply chain vulnerabilities.
• Strategic partnerships with CMOs facilitate scalability but require thorough vetting.
• Regulatory developments and geopolitical factors significantly influence supply chain dynamics.

---

Frequently Asked Questions (FAQs)

1. What is the typical lead time for sourcing API components for HAILEY FE 1/20?
Lead times usually range from 3 to 6 months, depending on API complexity, supplier location, regulatory clearance, and logistical considerations.

2. Are there regional preferences for suppliers of HAILEY FE 1/20?
Regional preferences depend on regulatory markets; North American and European companies tend to prioritize suppliers with local GMP certifications, while Asian manufacturers are preferred for cost efficiency and scale.

3. How do supply chain disruptions impact the availability of HAILEY FE 1/20?
Disruptions can cause shortages, delays, and increased costs. Strategic stockpiling and multiple sourcing mitigate these risks.

4. What are the key regulatory hurdles for suppliers of HAILEY FE 1/20?
Compliance with GMP, validation of manufacturing processes, documentation accuracy, and adherence to pharmacopoeias are critical regulatory hurdles.

5. How can companies ensure quality standards when selecting suppliers?
Conduct comprehensive audits, review certification documentation, test batches, and monitor ongoing quality performance regularly.

---

References

1. US Food and Drug Administration (FDA). Good Manufacturing Practice (GMP) Regulations for Drugs.
2. European Medicines Agency (EMA). Manufacturing and Quality Control Standards.
3. GlobalAPI.com. API Manufacturers Directory.
4. IQVIA Institute. The Global Use of Medicines.
5. Statista. Pharmaceutical Supply Chain Trends.

---

Note: Accurate supplier identification for HAILEY FE 1/20 requires specific licensing and product information, which was not provided; this analysis covers the general framework applicable to similar pharmaceutical products.